Kiromic BioPharma, Inc. (KRBP)
USD 0.08
(-2.33%)
USD 0.08
(-2.33%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 12.16 Million USD | 1.68% |
| 2022 | 11.96 Million USD | -61.06% |
| 2021 | 30.72 Million USD | 139.52% |
| 2020 | 12.82 Million USD | 383.65% |
| 2019 | 2.65 Million USD | 202.82% |
| 2018 | 876 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 12.62 Million USD | 3.77% |
| 2024 Q2 | 12.46 Million USD | -1.3% |
| 2023 Q3 | 14.23 Million USD | 4.38% |
| 2023 Q2 | 13.63 Million USD | 4.03% |
| 2023 FY | 12.16 Million USD | 1.68% |
| 2023 Q1 | 13.1 Million USD | 9.53% |
| 2023 Q4 | 12.16 Million USD | -14.5% |
| 2022 Q3 | 13.01 Million USD | -33.3% |
| 2022 Q2 | 19.52 Million USD | -24.6% |
| 2022 FY | 11.96 Million USD | -61.06% |
| 2022 Q1 | 25.88 Million USD | -15.75% |
| 2022 Q4 | 11.96 Million USD | -8.08% |
| 2021 Q1 | 10.15 Million USD | -20.87% |
| 2021 FY | 30.72 Million USD | 139.52% |
| 2021 Q4 | 30.72 Million USD | -21.12% |
| 2021 Q3 | 38.95 Million USD | 504.99% |
| 2021 Q2 | 6.43 Million USD | -36.58% |
| 2020 Q3 | 3.18 Million USD | -18.07% |
| 2020 Q2 | 3.88 Million USD | -13.14% |
| 2020 FY | 12.82 Million USD | 383.65% |
| 2020 Q1 | 4.46 Million USD | 68.47% |
| 2020 Q4 | 12.82 Million USD | 303.44% |
| 2019 Q4 | 2.65 Million USD | 0.0% |
| 2019 FY | 2.65 Million USD | 202.82% |
| 2018 FY | 876 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| America Great Health | 299.12 Thousand USD | -3968.145% |
| Ampio Pharmaceuticals, Inc. | 5.73 Million USD | -112.151% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | 17.19% |
| Biora Therapeutics, Inc. | 31.21 Million USD | 61.016% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -277.919% |
| Better Therapeutics, Inc. | 22.94 Million USD | 46.96% |
| Calithera Biosciences, Inc. | 28.67 Million USD | 57.564% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -226.499% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | 40.766% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | 42.39% |
| Evelo Biosciences, Inc. | 64.44 Million USD | 81.116% |
| Evolutionary Genomics, Inc. | 2.35 Million USD | -417.014% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | 82.86% |
| Galera Therapeutics, Inc. | 26.14 Million USD | 53.449% |
| Innovation1 Biotech Inc. | 75.99 Thousand USD | -15913.317% |
| Molecular Templates, Inc. | 35.38 Million USD | 65.608% |
| Navidea Biopharmaceuticals, Inc. | 4.37 Million USD | -178.365% |
| NexImmune, Inc. | 8.59 Million USD | -41.6% |
| Orgenesis Inc. | 14.55 Million USD | 16.376% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -3.11% |
| Point of Care Nano-Technology, Inc. | 124.64 Thousand USD | -9663.083% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -114.228% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -3002.24% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 97.426% |
| Statera Biopharma, Inc. | 21.16 Million USD | 42.517% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -20.426% |
| Trevena, Inc. | 40.6 Million USD | 70.031% |
| Vaxxinity, Inc. | 44.35 Million USD | 72.563% |
| Vaccinex, Inc. | 3.63 Million USD | -235.142% |
| Vicapsys Life Sciences, Inc. | 39.65 Thousand USD | -30586.403% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | 78.535% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -2089.792% |